New 24,000-square-foot state-of-the-art facility will facilitate the build-out of Ventus’ pipeline, enabled by the vision to develop its ReSOLVE™ platform into a disruptive drug discovery platform
Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary, machine learning-enabled, computational chemistry platform, ReSOLVE™, and its deep protein science expertise to develop differentiated small molecule therapeutics, today announced the opening of a new laboratory and office facility in Montreal, Canada. The new 24,000-square-foot state-of-the-art facility more than doubles Ventus’ laboratory and office space in Montreal and allows Ventus to strategically expand its R&D capacity to enable the continued growth of its pipeline and further development of its proprietary ReSOLVE™ platform.
“This new facility expands our presence in Montreal and augments our existing facilities in Waltham, MA,” said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “The Montreal expansion will provide us with an increased footprint that enables us to enhance our R&D efforts, including further building out our ReSOLVE™ platform. ReSOLVE™ has already enabled three clinical-stage compounds, including our first-in-clinic, orally administered cGAS inhibitor, an important target for multiple autoimmune disorders that has remained elusive to other drug discovery approaches. ReSOLVE™ is a powerful ML-enabled drug discovery engine that can be leveraged across multiple therapeutic areas to rapidly identify and develop novel small molecule drugs for undruggable targets.”
The new facility serves as Ventus’ Montreal-based offices and laboratories for its drug discovery and development organization, including its medicinal chemistry, computational chemistry, DMPK, and disease biology teams. This new facility represents the second phase of Ventus’ global expansion and augments Ventus’ 13,000-square-foot facility in Waltham, Massachusetts, which houses Ventus’ corporate offices and laboratories for its structural biology, biochemistry, protein sciences, molecular biology, and cellular biology teams.
“We have already validated ReSOLVE™ for many targets, including those deemed undruggable,” said Ventus Chief Scientific Officer, Michael Crackower, Ph.D. “Our new lab facility will be pivotal in advancing our vision to further develop ReSOLVE™ into a disruptive small-molecule platform that will revamp traditional drug discovery with unprecedented efficacy and speed.”
About Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. Using its proprietary drug discovery platform, ReSOLVE™, the company screened its first target in 2020, selected three development candidates in 2022, and advanced its two wholly-owned product candidates into the clinic in 2023: VENT-03, a potent, selective, oral cGAS inhibitor in Phase 1, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor that has completed Phase 1. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These programs exemplify Ventus’ robust discovery capabilities and focus on differentiated programs for multi-indication immunology and neurology targets. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause Ventus’ actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other similar expressions. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Ventus’ development plans and the expansion of Ventus’ R&D capacity to enable the continued growth of its pipeline and further development of its proprietary ReSOLVE™ platform. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Ventus’ control, you should not rely on these forward-looking statements as predictions of future events. Such risks include, but are not limited to, the risk that Ventus is unable to further advance VENT-02 and VENT-03 in clinical development, obtain regulatory approval, and ultimately commercialize VENT-02 and VENT-03, or experience significant delays in doing so; that Ventus will require substantial additional funding to finance its operations; that the development and commercialization of pharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable; and that Ventus’ success depends on its, its current and future licensors’, and its exclusive licensees’ ability to obtain, maintain, enforce, and protect its intellectual property and its proprietary technologies. Forward-looking statements included herein are based upon information available to Ventus as of the date of this press release, and while Ventus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and Ventus’ statements should not be read to indicate that it has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Ventus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715498574/en/
Contacts
Media
Dan Budwick
1AB
dan@1abmedia.com
